Accent Microcell Limited has accepted the resignation of Mr. Chintan Umeshkumar Bhatt from the position of Non-Executive Independent Director, effective June 29, 2026. The resignation was submitted due to the director's inability to devote sufficient time and attention to the affairs of the company. This development impacts the company's board composition and committee leadership.

Consequent to the resignation, Mr. Bhatt has also ceased to be the Chairman of the Nomination and Remuneration Committee of the company with effect from June 29, 2026. The Board of Directors will place on record its appreciation for his contributions during his tenure at its ensuing meeting. The company confirmed that there are no other material reasons for the resignation other than those stated in the letter.

The disclosures were made to the National Stock Exchange of India Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The resignation letter confirmed that the director does not hold directorships in any other listed entities.

Details of Resignation

Accent Microcell Limited has released its audited financial results for the half year and financial year ended March 31, 2026. The company reported a total income from operations of ₹35579.95 lakh for the financial year 2025-26, compared to ₹27098.54 lakh in the previous year. Net profit for the year after tax stood at ₹4385.86 lakh, an increase from ₹3306.29 lakh in the corresponding period of the previous year.

Financial Performance

The board of directors approved the financial results at their meeting held on May 12, 2026. For the half year ended March 31, 2026, the company recorded a total income from operations of ₹21383.24 lakh and a net profit of ₹2578.03 lakh. Earnings per share (EPS) for the full year increased to ₹18.65 from ₹14.91 in the previous year.

Dividend Declaration

The Board of Directors has recommended a final dividend of ₹1.00 (10%) per paid-up equity share of the face value of ₹10 each for the financial year 2025-26. This dividend is subject to the approval of the shareholders.

Capital Raise and Utilization

During the year ended March 31, 2026, the company issued 29,46,020 equity shares via a rights issue at an issue price of ₹135 per share, aggregating to ₹3977.13 lakh. The proceeds were primarily allocated for setting up a manufacturing plant for Microcrystalline Cellulose. Additionally, the company had previously raised ₹7840.00 Lakhs through an IPO, with funds utilized for setting up plants for manufacturing Crosacmellose Sodium (CCS), Sodium Starch Glycolate (SSG), and Caboxymethylcellulose (CMC).

Operational Updates and Future Outlook

Management provided an update on Unit 3 during the earnings conference call held on May 16, 2026. Phase 1 of Unit 3, with a capacity of 2,400 metric tons, is expected to commence commercial production by June 25, 2026, pending regulatory approvals including GPCV and pollution control licenses. The delay was attributed to external factors such as abnormal monsoons and licensing requirements. Phase 2, which will cater to MCC production, is expected to go live in March 2027. The company has purchased land for up to Phase 6, with Phase 3 tentatively planned for 2028.

The company reported a total sales volume of 15,000 metric tons in FY26, comprising approximately 70% manufacturing and 30% trading volumes. Export revenue increased to 63% of total sales from 53% in the previous year. Management indicated that blended profit margins are expected to increase by 2-3% with the commercialization of premium products like MCC Spheres and CCS.